Work

Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS G12C mutant non-small-cell lung cancer.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps8649

Authors: Benjamin J. Solomon, Wallace L. Akerley, Vinod Ganju, Jun Zhang, Alex Adjei, Melissa Lynne Johnson, Alexander I. Spira, Lei Deng, Edward B. Garon, So Yeon Kim, Richard Frank, Lyudmila Bazhenova, Rasha Cosman, Rachel Roberts-Thomson, Christos Karapetis, Yong Ben, Foster Gonsalves

Institutions: Peter MacCallum Cancer Centre, Huntsman Cancer Institute, University of Kansas Medical Center, Cleveland Clinic, Sarah Cannon, Fred Hutch Cancer Center, UCLA Health, Smilow Cancer Hospital, Norwalk Hospital, University of California San Diego, The Kinghorn Cancer Centre, Queen Elizabeth Hospital, Flinders Medical Centre, BridgeBio (United States), BridgeBio Oncology Therapeutics (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410804538

FWCI:

Cites:

Cited by:

Related to: 10